A liquid biopsy project with
ACTT Project - Access to Cancer Testing & Treatment in Response to COVID-19
Access to the ctDNA test FOLLOW IT Liquid Biopsy
Update – July 13 2022
Canexia Health will continue to provide Follow It testing under Project ACTT at no cost until September 31st for breast cancer and December 31st for lung cancer.
- The liquid biopsy test is available for lung and breast cancer.
Patients with colorectal cancers will be able to access Canexia Health’s tests on a patient-pay basis. Please contact Canexia Health directly regarding this option at firstname.lastname@example.org
Announced on July 15, 2020, the ACTT Project is a consortium led by Vancouver-based Canexia Health (formerly Contextual Genomics), which provides cancer patients (metastatic or relapse of breast, colorectal or non-small cell lung cancers) with access to tests and treatment options during the COVID-19 pandemic.
Supported by the Digital Technology Supercluster, the ACTT Project will deploy and enhance a liquid biopsy solution that requires only a simple blood draw that can help oncologists guide the choice of cancer treatment and clinical trial options for their patients, eliminating the need for many patients to go to the hospital for surgical biopsies.
The ACTT Project will enable 2,000 Canadian patients (from Quebec, Ontario, Saskatchewan and British Columbia) to access the FOLLOW IT test at no cost, through March 31, 2021, whereas the cost of using this test is usually paid by the patient.
FOLLOW IT is a liquid biopsy test using next-generation sequencing to detect mutations in circulating tumor DNA (ctDNA) in the blood.
Genolife is proud to be Canexia Health’s partner and to provide access to this project in Quebec.
Test Requisition for ctDNA test : FOLLOW ITTM Liquid Biopsy
Information for Healthcare Professionals
Currently, the ACTT project is available in Quebec, Ontario, Saskatchewan and British Columbia.
In Quebec, the collection service is provided by Genolife.
After receiving a test requisition from their oncologist, patients should contact Genolife to make an appointment for a blood drawn. Genolife can provide blood collection services across the province and will send the sample and documents directly to Canexia Health
The ACTT Project only accepts patients diagnosed with a relapse (suspected or known) or metastatic:
Non-small cell lung cancer
Patients can only be referred by their oncologist.
Please follow the instructions below:
Give the requisition to the patient along with a copy of the pathology report (and the molecular tests results, if any) and ask your patient to contact Genolife to take an appointment for blood collection
Tel: 1-844-440-5454 Fax: 1-418-641-8950 Email: email@example.com
The tests are performed at Canexia Health’s accredited clinical laboratory in Vancouver, British Columbia.
Canexia Health will provide the results to the ordering oncologist within 10 business days from the receipt of the blood sample.
FOLLOW IT is blood-based circulating tumor DNA (ctDNA) NGS multiplex panel that tests for 146 hotspots and 23 exons in 30 cancer genes that are known to be important in prognosis and treatment of multiple solid adult tumours. For the full gene list click here.
FOLLOW IT provides a detailed clinical report which includes interpretations of results, available clinical trials and current treatment options based on the molecular profile of the tumor. For a sample FOLLOW IT report, click here.
FOLLOW IT blood-based ctDNA test allows for a less invasive sampling than tissue biopsy, while providing the oncologist with genomic data. The genomic information provided may identify and help to select the most relevant targeted therapies for your patient. For a list of associated genes and treatments, click here.
FOLLOW IT is focused on actionable results, including biomarkers associated with response to FDA and Health Canada approved therapies, as well as current Canadian clinical trials. The FOLLOW IT report can help guide treatment options available to the patient that may not be accessible without this advanced molecular testing.